Niagen Bioscience, Inc.
NAGE
$9.88
-$0.16-1.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.72% | -29.47% | 282.27% | 12,620.00% | 96.95% |
| Total Depreciation and Amortization | 0.51% | -45.53% | -2.19% | 76.81% | -4.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,223.21% | 98.62% | -643.45% | -45.84% | 13.76% |
| Change in Net Operating Assets | -260.54% | -47.54% | 916.10% | 127.38% | -185.69% |
| Cash from Operations | -84.14% | -8.16% | 145.58% | 1,423.86% | -189.49% |
| Capital Expenditure | -321.88% | 53.62% | -68.29% | -241.67% | 70.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -321.88% | 53.62% | -228.57% | -75.00% | 70.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -50.00% | 50.00% | -100.00% | 33.33% |
| Issuance of Common Stock | 20.49% | -17.86% | 263.47% | 74.41% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 85.37% | -- | -- | 100.00% |
| Cash from Financing | 20.55% | -17.16% | 260.73% | 74.33% | 4,357.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.66% | -10.65% | 171.70% | 1,310.31% | 33.33% |